Free Trial
TSE:HBP

Helix BioPharma 10/27/2023 Earnings Report

Helix BioPharma logo
C$0.96 0.00 (0.00%)
As of 05/2/2025

Helix BioPharma EPS Results

Actual EPS
-C$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Helix BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Helix BioPharma Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Helix BioPharma Earnings Headlines

The Man I Turn to In Times Like This
A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.
Helix BioPharma Reports Fiscal Loss, Refocuses Strategy
HBP:CA Helix BioPharma Corp.
Helix Biopharma: Fiscal Q2 Earnings Snapshot
See More Helix BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Helix BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Helix BioPharma and other key companies, straight to your email.

About Helix BioPharma

Helix BioPharma (TSE:HBP) Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

View Helix BioPharma Profile

More Earnings Resources from MarketBeat